Genetic/familial high-risk assessment: breast and ovarian.

By M. Daly, J. Axilbund, S. Buys, B. Crawford, C. Farrell, S. Friedman, J. Garber, S. Goorha, Stephen B. Gruber, H. Hampel and 15 more. The Journal of the National Comprehensive Cancer Network, 2010

821 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/dff4226e639d2ad83e4cdae9b4bb3bd298f5adc3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Reproductive Medicine

1. D. K. Armstrong
2. D. Jelovac

Citations in the corpus

• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “Treatment of germline genetic predisposition Of the 394 genes, which have been causally implicated in human cancer, some 10% are transmitted in the germline leading to increased susceptibility [42].”
• Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, background): “RRSO is the most definitive risk reduction strategy for ovarian cancer and should be considered in women with a known BRCA mutation who have completed childbearing.(28)”